Anti-CNNM4/ ACDP4 monoclonal antibody

Anti-CNNM4/ ACDP4 antibody for FACS & in-vivo assay

Target products collectionGo to CNNM4/CNNM4 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP0313-Ab-1/ GM-Tg-hg-MP0313-Ab-2Anti-Human CNNM4 monoclonal antibodyHuman
GM-Tg-rg-MP0313-Ab-1/ GM-Tg-rg-MP0313-Ab-2Anti-Rat CNNM4 monoclonal antibodyRat
GM-Tg-mg-MP0313-Ab-1/ GM-Tg-mg-MP0313-Ab-2Anti-Mouse CNNM4 monoclonal antibodyMouse
GM-Tg-cynog-MP0313-Ab-1/ GM-Tg-cynog-MP0313-Ab-2Anti-Cynomolgus/ Rhesus macaque CNNM4 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP0313-Ab-1/ GM-Tg-felg-MP0313-Ab-2Anti-Feline CNNM4 monoclonal antibodyFeline
GM-Tg-cang-MP0313-Ab-1/ GM-Tg-cang-MP0313-Ab-2Anti-Canine CNNM4 monoclonal antibodyCanine
GM-Tg-bovg-MP0313-Ab-1/ GM-Tg-bovg-MP0313-Ab-2Anti-Bovine CNNM4 monoclonal antibodyBovine
GM-Tg-equg-MP0313-Ab-1/ GM-Tg-equg-MP0313-Ab-2Anti-Equine CNNM4 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP0313-Ab-1/ GM-Tg-hg-MP0313-Ab-2; GM-Tg-rg-MP0313-Ab-1/ GM-Tg-rg-MP0313-Ab-2;
GM-Tg-mg-MP0313-Ab-1/ GM-Tg-mg-MP0313-Ab-2; GM-Tg-cynog-MP0313-Ab-1/ GM-Tg-cynog-MP0313-Ab-2;
GM-Tg-felg-MP0313-Ab-1/ GM-Tg-felg-MP0313-Ab-2; GM-Tg-cang-MP0313-Ab-1/ GM-Tg-cang-MP0313-Ab-2;
GM-Tg-bovg-MP0313-Ab-1/ GM-Tg-bovg-MP0313-Ab-2; GM-Tg-equg-MP0313-Ab-1/ GM-Tg-equg-MP0313-Ab-2
Products NameAnti-CNNM4 monoclonal antibody
Formatmab
Target NameCNNM4
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-CNNM4 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species CNNM4/ ACDP4 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP0313
    Target NameCNNM4
    Gene ID26504,94220,363216,710069,481346,101091529,522382
    Gene Symbol and Synonyms5430430O18Rik,ACDP4,CNNM4
    Uniprot AccessionQ6P4Q7,P0C588
    Uniprot Entry NameCNNM4_HUMAN,CNNM4_RAT
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000158158
    Target ClassificationN/A

    The target: CNNM4, gene name: CNNM4, also named as ACDP4. This gene encodes a member of the ancient conserved domain containing protein family. Members of this protein family contain a cyclin box motif and have structural similarity to the cyclins. The encoded protein may play a role in metal ion transport. Mutations in this gene are associated with Jalili syndrome which consists of cone-rod dystrophy and amelogenesis imperfecta. [provided by RefSeq, Feb 2010].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.